Suppressor of cytokine signaling 3 (SOCS3) is an important intracellular protein that inhibits cytokine signaling in numerous cell types and has been implicated in several inflammatory diseases. However, the expression and function of SOCS3 in osteoblasts are not known. In this study, we demonstrated that SOCS3 expression was transiently induced by LPS in osteoblasts, and apparently contributed to the inhibition of IL-6 induction by LPS treatment. We found that tyrosine 204 of the SOCS box, the SH2 domain, and the N-terminal kinase inhibitory region (KIR) of SOCS3 were all involved in its IL-6 inhibition. Furthermore, we demonstrated that CCAAT/enhancerbinding protein (C/EBP)  was activated by LPS (increased DNA binding activity), and played a key role in LPS-induced IL-6 expression in osteoblasts. We further provided the evidence that SOCS3 functioned as a negative regulator for LPS response in osteoblasts by suppressing C/EBP DNA binding activity. In addition, tyrosine 204 of the SOCS box, the SH2 domain, and the N-terminal kinase inhibitory region (KIR) of SOCS3 were all required for its C/EBP inhibition. These findings suggest that SOCS3 by interfering with C/EBP activation may have an important regulatory role during bone-associated inflammatory responses.
SOCS3 belongs to the family of suppressors of cytokine signaling (SOCS)2 proteins, which is induced by a number of mediators, including LPS, TNF-␣, as well as IL-6 and IL-10 (1-3). SOCS3 has been shown to function as a proinflammatory mediator by suppressing IL-6-gp130 signaling, interfering with its ability to inhibit LPS signaling (4, 5). For example, mice lacking SOCS3 in macrophages and neutrophils are resistant to LPS-induced shock (4). In contrast, accumulating data suggest that SOCS3 may suppress inflammatory responses (6). Thus, the function of SOCS3 during inflammation seems to be dependent on the particular disease model used and cell type studied. Moreover, the precise role of SOCS3 in LPS responses remains enigmatic.The stimulation of Toll-like receptor (TLR) 4 by LPS plays a critical role in innate immune responses in mammals. Although most studies on LPS-induced inflammation and the ensuing tissue destruction have been focused on immune systems, recent studies demonstrate that osteoblasts also express functional TLR4, which may play an important role in the pathogenesis of LPS-mediated bone disorders (2,7,8). For example, LPS stimulates osteoblasts to secrete receptor activator of NF-B ligand (RANKL), IL-6, IL-1, TNF-␣, GM-CSF, and PGE 2 , each of which seems to to be involved in LPS-mediated bone resorption (9). Among these proinflammatory mediators, IL-6 regulation in bone is extremely important for tissue homeostasis. Inappropriate expression of IL-6 has been suggested to have an impact on the increase in bone resorption observed in several bone inflammatory diseases (10, 11). Stimulation of IL-6 mRNA synthesis by LPS in human osteoblasts has been suggested to occur through CD14, p38 MAPK, and MEK (12). Several transcription factors s...